Answers are grounded in this paper and cite their sources.
Introduction Aggressive breast cancers, including triple‐negative and therapy‐resistant subtypes, remain clinically challenging due to molecular heterogeneity, adaptive resistance, and limited therapeutic penetration into tumor cores. Despite advances in nanomedicine and targeted therapies, current drug delivery strategies are constrained by poor tumor specificity, inadequate intracellular delivery, and limited engagement with the tumor microenvironment. Electroacupuncture (EA), extracellular vesicle (EV)‐mediated delivery, and plant-derived metabolites have each been investigated in relation to these challenges. However, their integration as a three-component therapeutic strategy has not been experimentally established in breast cancer. This review examines whether findings reported separately for these modalities suggest biological processes that may be complementary in aggressive breast cancer. Methods A systematic literature search was conducted across multiple scientific databases, with study identification, screening, eligibility assessment, and reporting undertaken in accordance with PRISMA 2020. The available evidence relating to EA, EV‐mediated delivery, and plant‐derived metabolites was critically examined to identify reported biological effects and potential areas of complementarity. Results EVs were evaluated as potential biological cargo carriers whose uptake and distribution depend on their source, composition, and experimental context. Plant‐derived metabolites were examined for their reported effects on cancer‐associated processes, including nuclear factor kappa B (NF‐κB) signaling, reactive oxygen species (ROS)‐associated mitochondrial dysfunction, and tumor–immune interactions. EA was considered as a potential physiological modulator, with reported effects on vascular function, neuroimmune signaling, and redox processes in different experimental settings. The synthesis identified similarities across separate studies in reported findings relating to vascular function, intracellular stress signaling, and immune regulation. No eligible study evaluated all three modalities together in a breast cancer model. Discussion The findings informed a hypothesis-generating framework for investigating possible relationships among EA, EV‐mediated delivery, and plant-derived metabolites. These proposed relationships remain untested and do not establish interactions or a shared mechanism. Future investigations should address the experiments required to evaluate the proposed combination, alongside pharmacological validation, vesicle manufacturing, quality control, and regulatory challenges. Direct preclinical validation is required before conclusions regarding mechanistic interactions, causality, safety, or therapeutic benefit can be drawn.
No takes yet. Share an insight, caveat, or question.
Kgosiemang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: